Pharmacokinetics and hematologic toxicity of linezolid in children: a prospective, two-center cohort study.

ABSTRACT: Despite the widespread pediatric use of linezolid, data on its hematologic toxicity-particularly among children exposed to anticancer chemotherapy-remain limited and inconsistent. This study aimed to evaluate linezolid-induced hematotoxicity through pharmacokinetic analysis, with an emphasis on chemotherapy-exposed pediatric patients. This dual-center prospective study assessed linezolid pharmacokinetics and clinical profiles in chemotherapy-stratified pediatric cohorts, examining associations with hematologic toxicity. Among 229 pediatric patients (65 with cancer), hematologic toxicity occurred in 43.2%, with significantly higher risks of leukopenia (hazard ratio [HR] 20.29, 95% confidence interval [CI]: 3.98-103.38), neutropenia (HR 2.60, 95% CI: 1.00-6.77), and thrombocytopenia events (

SUBMITTER: Zhu L 

PROVIDER: S-EPMC12406672 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature